Managing Consultant Appointed To KMI
Mr. Wyrick possesses an extensive background in quality systems (computer validation, infrastructure qualification, supplier management, and PDA Part 11) and quality assurance. As Global Quality Advisor for Eli Lilly Company, he was responsible for establishing and maintaining global quality programs to comply with industry standards and regulatory governance. Mr. Wyrick has represented Eli Lilly on various industry quality organization committees and with FDA personnel to establish quality system best practices.
A featured speaker and lecturer at conferences and seminars, Mr. Wyrick is a member of the Computer Validation Network Advisory Board, the United Kingdom Good Automated Manufacturing Practices Industry Board and the Editorial Advisory Board for Pharmaceutical Technology. He has served the past three-terms as Chairman of the Pharmaceutical Research and Manufacturing Association Computer System Validation Committee and currently chairs the Parenteral Drug Association (PDA) Computer Validation Interest Group Steering Committee.
(more)
-2- KMI (Wyrick)
He received a Bachelors degree in Computer Science from Indiana University/Purdue University at Indianapolis.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected future growth and customer demand. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: the cancellation or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. These factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 1999.
KMI provides knowledge and technology in the areas of compliance, validation and information systems. Its software development division, KMI Systems, provides a suite of integrated software applications for GMP-regulated companies. The company's website address is www.kminc.com.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that accelerate time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. The Company's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, Mass., PAREXEL operates in 43 locations throughout 29 countries around the world, and has approximately 4,275 employees.
<%=company%>